Introduction
============

Antiretroviral therapy (ART) has transformed the HIV-1 epidemic into a manageable chronic disease \[[@R1]--[@R3]\]. However, HIV reservoirs persist in resting CD4^+^ T cells \[[@R3]--[@R11]\] and viral rebound occurs upon ART interruption \[[@R12],[@R13]\] despite low frequencies of infected CD4^+^ T cells \[[@R3],[@R14]--[@R18]\]. Given the challenges related to lifelong ART treatment such as adherence, viral escape, toxicity, and cost, combined with suboptimal drug penetration into anatomic sanctuaries \[[@R19]--[@R21]\], the identification of rare cell subsets that carry HIV reservoirs based on surface markers and the implementation of latency reversal strategies represent major research priorities \[[@R3],[@R14],[@R15],[@R17],[@R22]--[@R25]\].

HIV reservoirs are defined as long-lived latently infected cells that allow persistence of replication-competent HIV for years during ART \[[@R3],[@R15],[@R17]\]. The HIV and simian immunodeficiency virus (SIV) exploit the long-lived properties of central memory (T~CM~) and transitional memory CD4^+^ T cells to ensure its persistence \[[@R26]--[@R29]\]. Effector memory (T~EM~) CD4^+^ T cells also harbor replication-competent HIV in ART-treated individuals \[[@R27],[@R30]\], but their contribution may be lower compared with T~CM~\[[@R31]\]. Moreover, follicular helper T cells are permissive to infection \[[@R32]\] and represent an important HIV reservoir during ART \[[@R33]\]. Furthermore, the finding that HIV reservoirs also persist in long-lived stem cell memory CD4^+^ T cells \[[@R30],[@R34]\] raised new challenges for HIV eradication strategies. Apart from their heterogeneity in terms of differentiation stage and anatomic localization, memory CD4^+^ T cells exhibit distinct polarization profiles tailored to their antigenic specificities \[[@R35]--[@R37]\]. In addition to Th1 and Th2, Th17 cells represent a third major lineage of CD4^+^ T cells specialized in maintaining immunity against pathogens at mucosal surfaces, including the gut \[[@R38],[@R39]\]. HIV/SIV efficiently replicate in Th17 as demonstrated by studies by our group and others \[[@R40]--[@R48]\]. More specifically, mucosal Th17 cells represent major targets of HIV/SIV infection \[[@R49],[@R50]\] and subsequent rapid depletion \[[@R51]--[@R57]\]. Consistent with this paradigm, a very recent study identified CCR6^+^RORgt^+^ Th17 as the first cells to be infected upon vaginal SIV challenge \[[@R58]\]. The developmental plasticity \[[@R59],[@R60]\], combined with the long-lived properties of Th17 cells \[[@R61],[@R62]\], recently raised new questions relative to their potential contribution to HIV persistence during ART. Although the contribution of blood Th17 to HIV reservoir persistence during ART is supported by recent studies by our group \[[@R63]\] and others \[[@R64],[@R65]\], this aspect remains poorly investigated at mucosal sites. Further studies in this area are important to orient new cell subset-targeted eradication strategies.

Herein, we investigated the contribution of colon and blood memory CD4^+^ T-cell subsets expressing the chemokine receptor CCR6 to HIV persistence during ART and the presence of replication-competent HIV in these cells.

Material and methods
====================

Study participants
------------------

HIV-infected individuals with undetectable plasma viral load receiving ART (\<40 copies HIV RNA/ml; HIV^+^ on ART (B20-B32), one elite controller (EC1; CD4 cell counts: 753 cells/μl; time since infection: 258 months; untreated: 61-year old), and uninfected volunteers were recruited at the McGill University Health Centre (Table [1](#T1){ref-type="table"}). Sigmoid biopsies (≈32 biopsies/donor) were collected during colonoscopy. Biopsies were processed using Liberase DL (Roche Diagnostics, Mannheim, Germany), as previously described \[[@R66],[@R67]\]. Matched peripheral blood samples (20 ml/donor) were collected from biopsy donors the same day. Finally, leukaphereses were collected from other HIV^+^ individuals on ART (ART \#01--19) and uninfected individuals (Table [1](#T1){ref-type="table"}), as previously reported \[[@R68]\]. Plasma viral load was measured using the Amplicor HIV-1 monitor ultrasensitive method (Roche) (Roche Diagnostics Systems, Branchburg, New Jersey, USA). The date of infection was estimated using clinical and laboratory data as well as patient history information. Peripheral blood mononuclear cells were isolated by gradient density centrifugation \[[@R41],[@R43]\] and frozen.

Ethics statement
----------------

The study using sigmoid biopsies and blood from HIV-infected and uninfected study participants was conducted in compliance with the principles included in the Declaration of Helsinki and received approval from the Institutional Review Board of the McGill University Health Centre and CHUM-Research Centre. All study participants signed a written informed consent for their study participation.

Flow cytometry analysis
-----------------------

The following fluorochrome-conjugated antibodies (Abs) were used for polychromatic flow cytometry analysis: CD3-Pacific-blue (UCHT1), CD4-Alexa-Fluor 700 (RPA-T4), CCR4-PE-Cy7 (1G1), CCR6-PE (11A9), CCR7-PE-Cy7 (3D12), CXCR3-PE-Cy5 (1C6) (BD Biosciences, San Diego, California, USA), CCR7-FITC (150503) (R&D Systems, Minneapolis, Minnesota, USA), CD45RA-APC-eFluor780 (HI100) (eBioscience, San Diego, California, USA), CD3-Alexa700 (UCHT1), CD326-BV650 (9C4), CD8-PerCP-Cy5.5 (RPA-T8), CD19-PerCP-Cy5.5 (HIB19), CD66b-PerCP-Cy5.5 (G10F5), human leukocyte antigen - antigen D related (HLA-DR)-BV785 (L243; Biolegend ,San Diego, California USA), CD4-FITC (SFCI12T4D11), and HIV-p24-RD1 (FH190--1--1); (Beckman Coulter, Fullerton, California, USA). Live/Dead Fixable Aqua Dead Cell Stain Kit (Vivid; Life Technologies, Burlington, Ontario, Canada) was used to exclude dead cells. Cells were analyzed by fluorescence-activated cell sorting (FACS) using the BD-LSRII cytometer and BD-Diva (BD Biosciences) and FlowJo (Tree Star, Inc., Ashland, Oregon, USA) softwares. All Abs were titrated for an optimal noise/signal ratio and Ab cocktails were validated by comparing single with multiple staining. Positive gates were placed based on fluorescence minus one controls \[[@R41],[@R69]\].

Cell sorting
------------

CD4^+^ T cells were sorted by magnetic-activated cell sorting and FACS, as previously described \[[@R41],[@R43],[@R45],[@R47]\]. Briefly, cells stained with Abs were suspended (40 × 10^6^ cells/ml) in sorting media (PBS 1× with 5% fetal bovine serum (FBS) and 25 mmol/l Hepes buffer) and sorted using the BD-FACSAriaIII (BD Biosciences). The sorting gates were set using fluorescence minus one controls \[[@R41],[@R69]\]. The viability staining Vivid (Life Technologies) was included in each staining cocktail to exclude dead cells. Sorted subsets were in average more than 99% pure based on CD4, CD45RA, and CCR6 expression and more than 90% based on CCR7, CCR4, and CXCR3 expression (Suppl. Figures 2 and 4).

RT-PCR for CCR6 mRNA detection
------------------------------

Total RNA was isolated using RNeasy kit (Qiagen Inc., Hilden, Germany), as previously described \[[@R45],[@R47]\]. One-step reverse transcription PCR (RT-PCR) (Qiagen Inc., Toronto Ontario, Canada) using CCR6 Quantitect primers (Qiagen Inc., Toronto) was carried out in an Eppendorf Mastercycler PCR System (Applied Biosystems, Foster City, California, USA). The products of RT-PCR amplifications were visualized on a 1% agarose gel. Reactions were performed in the presence and absence of reverse transcriptase to distinguish between genomic DNA and mRNA amplification.

HIV DNA quantification
----------------------

The quantification of total and integrated HIV DNA was performed by nested real-time PCR using specific primers and amplification conditions, as we previously described \[[@R27],[@R41],[@R43],[@R45],[@R47]\].

HIV reactivation assay
----------------------

Cells were cultured in 48-well plates at 2 × 10^6^ cells/well/ml in the presence of immobilized CD3 and soluble CD28 Abs (1 μg/ml). Cells were cultured in the presence or absence of all-trans retinoic acid (ATRA, 10 nmol/l). At days 3, 6, and 9, media was refreshed with RPMI 1640 containing FBS (10%) and IL-2 (5 ng/ml) and/or ATRA. HIV p24 levels were quantified using a homemade ELISA assays \[[@R27],[@R41],[@R43],[@R45],[@R47]\]. The intracellular expression of HIV p24 was quantified by flow cytometry upon staining with appropriate Abs using the Cytofix/Cytoperm kit (BD Biosciences).

IL-17A ELISA
------------

IL-17A levels in cell culture supernatants were quantified by a specific ELISA assay (eBiosciences).

Statistical analysis
--------------------

Statistical analyses were performed using the GraphPad Prism 5 software (GraphPad Software, Inc., La Joya, California, USA). Briefly, paired *t*-test *P* values were calculated for the comparison between two sets of matched samples, Friedman with Dunn\'s multiple comparisons tests were applied to determine statistical significance for differences between multiple matched cell subsets, and Mann--Whitney *P* values were calculated for comparisons between unmatched groups.

Results
=======

Colon and blood memory CCR6^+^ T cells are enriched in HIV DNA
--------------------------------------------------------------

To study the contribution of CD4^+^ T-cell subsets expressing the chemokine receptor CCR6 to HIV persistence during ART, matched sigmoid biopsies and blood samples were collected from *n* = 13 ART-treated chronically HIV-infected individuals with undetectable plasma viral load (\<40 HIV RNA copies/ml; Table [1](#T1){ref-type="table"}; B20-B32) and EC1. Memory CCR6^+^ and CCR6^−^ CD3^+^CD4^+^CD45RA^−^ T cells negative for CD8, CD19, CD66b, and CD326 were analyzed for frequency and HLA-DR expression and sorted by flow cytometry for HIV DNA quantification (Fig. [1](#F1){ref-type="fig"}a). The frequency of CD3^+^, CD3^+^CD4^+^, and CD3^+^CD4^+^CCR6^+^ T cells was similar in the colon of HIV^±^ on ART compared with uninfected individuals (Table [1](#T1){ref-type="table"}); nevertheless, the frequency of blood CD3^±^CD4^±^ T cells was significantly reduced (Suppl. Figure 1A-C), consistent with differences in the CD4 cell counts between the two cohorts (Table [1](#T1){ref-type="table"}). The frequency of memory CCR6^+^ T cells was significantly higher in the colon versus blood of both HIV^+^ on ART (Fig. [1](#F1){ref-type="fig"}b) and uninfected controls (Suppl. Figure 1C). An increased expression of the activation marker HLA-DR was observed on memory CD3^+^CD4^+^ T cells expressing CCR6 versus CCR6^−^ T cells from the colon but not the blood of HIV^+^ on ART (Fig. [1](#F1){ref-type="fig"}c and d), with similar differences being observed in uninfected individuals (Suppl. Figure 1D-E). The pool of CCR6^+^ T cells in the gut compared with blood was enriched in cells with a CXCR3^+^ phenotype (Fig. [1](#F1){ref-type="fig"}e), suggesting a Th1Th17 polarization of these cells \[[@R41],[@R70]\]. These findings indicate that the colon is a preferential site for CCR6^+^ T-cell infiltration and that these cells are activated in the colon regardless of the HIV status.

![Phenotypic analysis and HIV DNA quantification in colon and blood CCR6^+^ and CCR6^−^ T-cell subsets.](aids-31-035-g001){#F1}

Memory CCR6^+^ and CCR6^−^ T cells from matched sigmoid biopsies and blood were further sorted and levels of total HIV DNA (Gag, late reverse transcripts) were quantified by nested real-time PCR \[[@R27],[@R41]\]. Results in Fig. [1](#F1){ref-type="fig"}f and g demonstrate significantly higher levels of HIV DNA in CCR6^+^ versus CCR6^−^ T cells from both blood (*P* = 0.026; median 1.5-fold increase) and colon (*P* = 0.0014; median 2.8-fold increase). Although statistical significance was not reached, a fraction of donors exhibited higher HIV DNA levels in CCR6^+^ T cells from the colon versus blood, whereas HIV DNA levels in CCR6^−^ T cells from the colon versus blood were reduced (Fig. [1](#F1){ref-type="fig"}h). Of note, HIV DNA levels were low to undetectable in blood and colon CCR6^+^/CCR6^−^ T cells of the EC1 and two ART-treated individuals (B37, B30; Fig. [1](#F1){ref-type="fig"}f and g), in part because of limited numbers of sorted cells (typically between 3000 and 50 000 cells/subset/PCR). These results reveal that CCR6^+^ compared with CCR6^−^ T cells are highly enriched in the colon where they exhibit a superior state of activation and significantly contribute to the persistence of HIV DNA during ART in both colon and blood compartments.

Previous studies documented a transient downregulation of CCR6 expression upon T-cell receptor (TCR) triggering \[[@R71]\], raising the possibility that in HIV-infected study participants with chronic systemic immune activation, the CCR6^−^ fraction may be contaminated by formerly CCR6^+^ T cells. To test this possibility, highly pure total memory CCR6^+^/CCR6^−^ T cells sorted by flow cytometry (Suppl. Figure 2A) were analyzed for the expression of CCR6 mRNA by RT-PCR. In all donors, CCR6 mRNA was detected at higher levels in CCR6^+^ versus CCR6^−^ subsets, with CCR6 mRNA being detectable in the CCR6^-^ fractions of only two of five study participants (Suppl. Figure 2B). Thus, in some HIV-infected donors, CCR6^−^ T cells likely include a small fraction of CCR6^+^ T cells that downregulated CCR6 probably as a consequence of their activation *in vivo*.

Central memory CCR6^+^ T cells are major contributors to integrated HIV DNA reservoirs in the blood
---------------------------------------------------------------------------------------------------

We next studied the frequency and size of the HIV DNA reservoir in blood CCR6^+^/CCR6^−^ T cells with T~CM~ (CD45RA^−^CCR7^+^) and effector/transitional memory (T~EM/TM~, CD45RA^−^CCR7^−^) phenotypes, using well established surface markers \[[@R37]\]. Cell subsets were isolated from large numbers of peripheral blood mononuclear cells obtained by leukapheresis from aviremic HIV-infected study participants receiving ART for more than 11 months (Table [1](#T1){ref-type="table"}; ART\#01--19). Total CD4^+^ T cells from a subset of donors were first screened for the presence of total and integrated HIV DNA using nested real-time PCR \[[@R27],[@R41]\]. Levels of total versus integrated HIV DNA levels were always higher but the two measurements were positively correlated (Suppl. Figure 3). Using the gating strategy depicted in Fig. [2](#F2){ref-type="fig"}a, a reduced frequency of CCR6^+^ T~CM~ and most significantly CCR6^+^ T~EM/TM~ was observed in HIV^+^ on ART compared with HIV^−^ controls (Fig. [2](#F2){ref-type="fig"}b). Highly pure T-cell subsets were sorted by FACS (Fig. [2](#F2){ref-type="fig"}c) from *n* = 5 HIV^+^ individuals on ART (Table [1](#T1){ref-type="table"}) and used for the quantification of integrated HIV DNA. Despite typical donor-to-donor variations in the absolute numbers of integrated HIV DNA copies/subset, the highest levels of integrated HIV DNA were observed in CCR6^+^ T~CM~ in 4/5 donors (Friedman *P* = 0.0031, *n* = 5; Fig. [2](#F2){ref-type="fig"}d and e). When the integrated HIV DNA copy numbers were normalized relative to the proportion of each cell subset, a tendency for a greater contribution of CCR6^+^ T~CM~ to the pool of proviral reservoir was observed, compared with other subsets (Fig. [2](#F2){ref-type="fig"}f).
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To further identify discrete T-cell subsets that contribute to HIV DNA persistence during ART, CCR4 and CXCR3 were used to identify T~CM~ with a Th17 (CCR6^+^CCR4^+^CXCR3^−^) and Th1Th17 (CCR6^+^CCR4^−^CXCR3^+^) polarization profile, as well as Th1 (CCR6^−^CCR4^−^CXCR3^−^) and Th2 (CCR6^−^CCR4^+^CXCR3^−^) \[[@R41],[@R70]\] (Fig. [3](#F3){ref-type="fig"}a). The frequency of T~CM~ with Th2 and Th17 but not Th1 and Th1Th17 phenotypes was significantly diminished in HIV^+^ on ART compared with HIV^−^ individuals (Fig. [3](#F3){ref-type="fig"}b; Table [1](#T1){ref-type="table"}). The four T~CM~ subsets were sorted by flow cytometry from *n* = 5 HIV^+^ individuals on ART, as previously described \[[@R41]\] (Suppl. Figure 4) and levels of integrated HIV DNA were quantified. Among T~CM~ cells, Th17 and Th1Th17 subsets harbored significantly higher levels of integrated HIV DNA compared with Th2 cells (Fig. [3](#F3){ref-type="fig"}c and d). Further, when the contribution to the pool of HIV reservoir was calculated relative to the proportion of cells per subset, T~CM~ with Th1Th17 as well as Th1 phenotypes contributed the most to the HIV DNA pool, whereas Th2 T~CM~ contributed the least (Fig. [3](#F3){ref-type="fig"}e). Although, differences in the relative contribution of Th17 versus Th2 to HIV reservoir did not reach statistical significance using the Dunn\'s multiple comparisons test, likely as a consequence of donor-to-donor variation in absolute HIV DNA levels as well as Th17 frequency (Fig. [3](#F3){ref-type="fig"}e), matched comparisons between Th17 and Th2 showed statistically significant differences (paired *t*-test *P* = 0.0036).

![Significant contribution of T~CM~ with Th17 and Th1Th17 phenotypes to the pool of HIV DNA reservoir.](aids-31-035-g003){#F3}

Together these results reveal the important although not exclusive contribution of CCR6^+^ T~CM~ cells with Th17 and Th1Th17 polarization phenotypes to the persistence of integrated HIV DNA during ART, despite their decreased frequency in the peripheral blood of HIV^+^ individuals on ART.

HIV reactivation occurs in subsets of memory CD4^+^ T cells expressing CCR6
---------------------------------------------------------------------------

We finally addressed the question whether CCR6^+^ T-cell subsets are enriched in replication-competent HIV. TCR triggering leads to optimal HIV reactivation in CD4^+^ T cells \[[@R24],[@R72]\]. Also, we previously demonstrated that ATRA increases HIV permissiveness in CCR6^+^ T cells *in vitro*\[[@R43]\]. To determine whether ATRA directly regulates the activity of the HIV promoter, pilot experiments were performed with HeLa Human cervical carcinoma cells (TZM-BL) cells, engineered to carry the luciferase gene under the control of HIV promoter, as well as in ACH2 cells \[a human T cell line derived from a leukemia donor (A3.01) infected with HIV\] harboring one copy of integrated HIV DNA per cell. Increased HIV promoter activity was observed in the presence of ATRA when TZM-BL cells were infected with replication-competent HIV or transfected with HIV-Tat (Suppl. Figure 5A-B) and HIV p24 levels were significantly increased in phorbol 12-myristate 13-acetate-treated ACH2 cells (Suppl. Figure 5C). Therefore, for an optimal HIV reactivation, T cells were stimulated with CD3/CD28 Abs and cultured in the presence or absence of ATRA, in the absence of ART, with IL-2 added at day 3 postculture (Fig. [4](#F4){ref-type="fig"}a). In contrast to the standard viral outgrowth assays (VOAs) \[[@R14]\], no target cells were added. Viral replication was measured by HIV p24 quantification by ELISA and flow cytometry. The Th17-specific effector cytokine IL-17A was almost exclusively detected in cell culture supernatants of the CCR6^+^ T~M~, T~CM~, and T~EM/TM~ fractions (Fig. [4](#F4){ref-type="fig"}b), indicative that contamination by activated T cells that downregulated CCR6 expression was minor. Consistent with their preferential infection (Figs. [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}), HIV reactivation occurred preferentially in CCR6^+^ versus CCR6^−^ T~M~, T~CM~, and T~EM/TM~ subsets in 3/3 study participants in the presence or absence of ATRA, as determined by the HIV p24 levels measured by ELISA in culture supernatants (Fig. [4](#F4){ref-type="fig"}c and d) and FACS quantification of HIV p24^+^ cell frequency (Fig. [4](#F4){ref-type="fig"}e and f). Of note, the effect of ATRA was more robust on CCR6^+^ T~EM/TM~ compared with T~M~ and T~CM~ subsets, and HIV reactivation failed in CCR6^+^ T~CM~ of ART \#15, whereas in the same donor HIV reactivation could be detected in T~M~ and T~EM/TM~ subsets (Fig. [4](#F4){ref-type="fig"}c--f). Together, these results provide evidence that the pool of memory CD4^+^ T cells carrying replication-competent HIV DNA is highly heterogeneous, that CCR6 is a marker for cells preferentially infected, and that ATRA may be used together with TCR triggering to outgrow HIV more efficiently in ART-treated study participants.
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Discussion
==========

In this study, we demonstrate that memory CD4^+^ T-cell subsets expressing the chemokine receptor CCR6 are enriched in HIV DNA in both colon and blood of HIV-infected individuals receiving ART. We also demonstrated that blood CCR6^+^ T cells with T~CM~ and Th17 and/or Th1Th17 phenotypes were enriched in integrated HIV DNA; and that HIV reactivation is induced more robustly in CCR6^+^ versus CCR6^−^ T~M~, T~CM~, and T~EM~, upon TCR triggering in the presence of ATRA. These findings are consistent with the concept that fractions of Th17 cells are long lived \[[@R61],[@R62],[@R63]\] and support HIV reservoir persistence during ART \[[@R63],[@R64],[@R65]\]. HIV uses the molecular machinery of the host cells for integration into specific sites \[[@R73]\]. Whether the integration landscape of HIV differs in CD4^+^ T-cell subsets with unique transcriptional profiles, such as CCR6^+^ T cells, and whether this leads to distinct mechanisms of HIV latency and reactivation remains to be determined in future studies.

CCR6 regulates cell migration into various anatomic sites including the intestinal mucosa \[[@R74]--[@R76]\]. CCR6 expression on CD4^+^ T cells is associated with the Th17 lineage commitment \[[@R41],[@R70],[@R77]\]. Although not all CCR6^+^ T cells produce IL-17, a major fraction of CCR6^+^IL-17A^−^ T cells become IL-17A^+^ upon exposure to specific signals *in vitro*\[[@R78]\]. This is consistent with the most recent Th17 polarization model that includes two distinct steps, specification and acquisition of effector functions \[[@R79]\]. Studies by our group and others previously demonstrated preferential HIV replication in memory CD4^+^CCR6^+^ T cells producing IL-17A \[[@R40]--[@R48]\]. The superior HIV permissiveness of CCR6^+^ versus CCR6^−^ T cells is explained by the relatively high expression of the HIV coreceptor CCR5 and the expression of multiple postentry HIV permissiveness factors \[[@R41]--[@R45],[@R47]\]. Consistently, CCR6^+^RORγt^+^ Th17 cells were identified very recently as the first targets of SIV infection upon vaginal challenge \[[@R58]\]. HIV infection *per se*, in addition to other possible mechanisms (e.g., altered trafficking into mucosal sites \[[@R75],[@R80]\], paucity of Th17 precursors \[[@R81],[@R82]\] and Th17-polarizing dendritic cell subsets \[[@R83]\], IL-21 deficit \[[@R84]\]), contribute to Th17 depletion from gut-associated lymphoid tissues thus causing dramatic alterations of intestinal barrier function \[[@R51]--[@R57]\]. ART fails to restore Th17 frequency/function at mucosal sites unless treatment is initiated during the very first days/weeks of infection \[[@R85]--[@R87]\]. Indeed, early ART initiation is the only strategy to reduce the size of HIV reservoirs \[[@R18],[@R26]\]. Our study provides original evidence that CCR6^+^ T cells are enriched in frequency in the colon versus blood of HIV^+^ on ART individuals and carry higher levels of HIV DNA compared with their CCR6^−^ counterparts. Our results also revealed that colon versus blood CCR6^+^ T cells exhibit an activated (HLA-DR^+^) phenotype. This raises the possibility that residual viral replication may occur in colon CCR6^+^ T cells during ART; however, the size of our sorted cell samples was too small to explore this possibility. HLA-DR expression on colon CCR6^+^ T cells was observed in both infected/uninfected individuals but whether this is the consequence of the interaction with local microbiota \[[@R88]\], remains to be investigated. Of note, colon compared with blood CCR6^+^ T cells were enriched in cells expressing CXCR3, corresponding to a Th1Th17 phenotype \[[@R70]\] that is associated with the highest levels of CCR5 expression \[[@R41],[@R42]\]. Finally, access to large leukapheresis samples allowed us to further explore the validity of CCR6 as a marker for cells enriched in HIV DNA. Despite the reduced frequency of cells expressing CCR6 in the blood of HIV^+^ on ART compared with uninfected individuals, we observed that total CCR6^+^ T~CM~ population, as well as CCR6^+^CCR4^+^ (Th17 phenotype) and/or CCR6^+^CXCR3^+^ (Th1Th17 phenotype) T~CM~, contributed most significantly to the pool of integrated HIV DNA. In contrast, cells with a Th2 phenotype (CCR4^+^CCR6^−^CXCR3^−^) carried the lowest levels of HIV DNA, likely because of their lack of CCR5 expression \[[@R41]\].

Our findings are consistent with those recently published by Sun *et al.*\'s \[[@R64]\] and Khoury *et al.*\'s \[[@R65]\] groups for peripheral blood CCR6^+^ T cells. All these findings are in line with a model in which the CCR6--CCL20 axis plays a critical role HIV latency establishment in resting CD4^+^ T cells \[[@R89]\] and support the need for early intervention to block HIV infection of CCR6^+^ T cells. Such strategies may include microbicides such as glycerol monolaurate, a compound that proved to be efficient in stopping SIV dissemination from the portal sites of entry in a simian model of infection \[[@R90]\]. Other strategies may be inspired from the most current understanding of molecular mechanisms regulating HIV permissiveness in CCR6^+^ Th17 \[[@R45],[@R47],[@R48],[@R91]\], to prevent new infection and HIV persistence in these cells during ART.

The 'gold standard' method for the quantification of replication-competent HIV reservoirs is the VOA \[[@R14],[@R24]\]. Given the limited number of memory CD4^+^CCR6^+^ T cells, we could isolate using leukapheresis samples of HIV^+^ on ART individuals, we established a modified VOA in which cells were stimulated via CD3/CD28 and cultured in the presence or absence of ATRA. We previously demonstrated that ATRA increases HIV replication specifically in CCR6^+^ T cells via entry (CCR5 upregulation) and postentry mechanisms \[[@R43]\]. Of note, retinoic acid (RA)-responsive elements (RARE) are present within the HIV long terminal repeat \[[@R92]\], supporting a direct effect of ATRA on the HIV promoter. This possibility is consistent with very recent studies that used acitretin, a second-generation retinoid, to kill latently infected cells upon HIV reservoir reactivation \[[@R93]\]. In addition to a potential therapeutic application \[[@R93]\], we propose the use of ATRA in VOA to detect replication-competent HIV in small biological samples isolated from patients upon various therapeutic interventions. By using this VOA, we demonstrated that HIV productive replication occurs more efficiently in memory CCR6^+^ compared with CCR6^−^ T cells.

One potential bias in our study is linked to the possibility that regulatory T cells (Tregs) are present in the CCR6^+^ T-cell fractions. Indeed, Tregs were reported to express CCR6, CCR4, and/or CXCR3 \[[@R82],[@R94]\], thus insuring their colocalization with Th17 subsets at various anatomic sites. In humans, Tregs can be identified as CD3^+^CD4^+^ T cells with a CD25^high^CD127^low^FoxP3^+^ phenotype \[[@R81],[@R95]\]. We previously reported that the expression of FoxP3 mRNA was minimal in CCR6^+^ T-cell subsets isolated from leukapheresis \[[@R41]\]. Nevertheless, considering the increased frequency of Tregs to the detriment of Th17 cells at mucosal sites \[[@R75],[@R96]\], the ability of Tregs to support HIV replication \[[@R97]\], as well as the ability to Th17 cells to transdifferentiate into Tregs \[[@R60]\], future studies are needed to distinguish the contribution of CCR6^+^ Th17 versus CCR6^+^ Tregs to HIV reservoir persistence during ART. Such studies will require larger biological samples from organ ectomy or autopsy tissues; there is also the need of using reliable Treg markers and functional assays for the identification of Tregs with suppressive activity, as FoxP3 expression was documented to be upregulated in conventional T cells upon TCR triggering \[[@R98]\].

One discrepancy in our study is represented by the fact that the depletion of Th17 cells was observed in the leukapheresis but not the sigmoid biopsy cohort. This discrepancy can be explained by differences in the technical procedure, age, and duration of ART, as well as the health status and composition of the CCR6^+^ T-cell pool (Th17, Tregs, etc.) in blood versus colon. Indeed, in the sigmoid biopsy cohort HIV^−^ controls were older compared with the HIV^+^ individuals (median: 60 versus 55-year old, Table [1](#T1){ref-type="table"}) and were included based on their need for cancer screening, with one being positive for hepatitis A and B viruses. Nevertheless, studies by other groups demonstrated the normalization of CD4^+^ T cell and Th17/Th22 frequencies in the sigmoid biopsies of HIV^+^ individuals upon long-term ART compared with HIV^−^ individuals \[[@R54],[@R99],[@R100]\]. Consistently, HIV^+^ individuals included in the sigmoid biopsy cohort received ART for a longer period of time compared with those in the leukapheresis cohorts (median: 72 versus 50 months), thus, suggesting a potential restoration of CCR6^+^ T cells in the colon and blood upon long-term ART. Finally, whether the contribution of CCR6^+^ versus CCR6^−^ T cells to HIV reservoirs differ at distinct mucosal sites such as ileum versus colon requires further investigations.

In conclusion, our findings identified CCR6 as a marker for CD4^+^ T cells enriched in HIV reservoirs in both colon and blood and emphasize the need for novel targeted cell-specific viral eradication strategies. To date, the only demonstrably curative intervention for HIV is bone marrow transplant using a donor homozygous for the CCR5/Δ32 deletion \[[@R101]\]. However, such strategies cannot be applied at large scale. Our current findings, together with those published by other groups \[[@R64],[@R65]\], point to the potential beneficial effect of a temporary depletion of CD4^+^CCR6^+^ T cells, depletion that may result in a significant reduction of HIV reservoirs in ART-treated individuals. Although the antibody-mediated depletion of B cells is beneficial for autoimmunity \[[@R102]\], the success of CCR6^+^CD4^+^ T-cell depletion in HIV-infected individuals will require careful investigations in animal models and clinical trials. Alternatively, the recent identification of positive/negative regulators of HIV replication preferentially expressed in Th17 cells \[[@R45],[@R47]\] open the path for developing new Th17-specific anti-HIV therapies.
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Demographic and clinical characteristics of study cohorts.

                                                                                Study cohorts                                                                                                                                        
  -------------------------------------------------------------------- -------- ------------------------------------------------------ --------------------------------------- ----------------------------------------------------- ---------------------------------------------------------
  Age (years)                                                          Median   55                                                     60                                      46                                                    45
                                                                       Range    50--67                                                 54--69                                  24--62                                                26--58
  Sex                                                                  M/F      13/0                                                   5/2[^a^](#TF1-1){ref-type="table-fn"}   15/5                                                  12/1
  Race                                                                 C/H/AA   12/1/0                                                 7/0/0                                   16/0/4                                                13/0/0
  CD4^+^ cell counts (cells/μl)                                        Median   679                                                    750                                     575                                                   745 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
                                                                       Range    175--985                                               456--1229                               269--886                                              375--1424 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
  CD8^+^ cell counts (cells/μl)                                        Median   914                                                    320                                     470                                                   362 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
                                                                       Range    489--1117                                              158--582                                240--1272                                             95--709 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
  CD4^+^/CD8^+^ ratios                                                 Median   0.67                                                   2.11                                    1.15                                                  2.38 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
                                                                       Range    0.16--2.01                                             1.83--2.89                              0.49--2.00                                            1.56--3.98 (*n* = 12[^b^](#TF1-2){ref-type="table-fn"})
  Time since infection (months)                                        Median   233                                                    N/A                                     153                                                   N/A
                                                                       Range    48--348                                                N/A                                     48--288                                               N/A
  ART[^c^](#TF1-3){ref-type="table-fn"}                                Yes      N/A                                                    Yes                                     N/A                                                   
  Time of aviremia[^d^](#TF1-4){ref-type="table-fn"} on ART (months)   Median   72 (*n* = 10[^b^](#TF1-2){ref-type="table-fn"})        N/A                                     50 (*n* = 17[^b^](#TF1-2){ref-type="table-fn"})       N/A
                                                                       Range    24--165 (*n* = 10[^b^](#TF1-2){ref-type="table-fn"})   N/A                                     11--85 (*n* = 17[^b^](#TF1-2){ref-type="table-fn"})   N/A

AA, African-American; ART, antiretroviral therapy; C, Caucasian; F, female; H, Hispanic; M, male; N/A, not applicable.

^a^One F was positive for Hepatitis A and B viruses.

^b^Data available on a fraction of donors only.

^c^ART consisted of a combination of two nucleoside reverse transcriptase inhibitors with either one nonnucleoside reverse transcriptase inhibitors, protease inhibitor, or integrase inhibitor.

^d^Plasma viral load \<40 HIV RNA copies/ml.
